Welcome to our dedicated page for Sangamo Therapeutics news (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics stock.
Sangamo Therapeutics Inc (NASDAQ: SGMO) is a clinical-stage biopharmaceutical leader pioneering genomic medicines through innovative gene editing and gene therapy approaches. This dedicated news hub provides investors and researchers with timely updates on the company's scientific advancements, regulatory milestones, and therapeutic developments.
Access authoritative updates including press releases on clinical trial progress, partnership announcements with biotech leaders, and research breakthroughs in neurology, hemophilia, and rare genetic disorders. Our curated collection ensures you stay informed about SGMO's pipeline developments, including zinc finger protein therapies and in vivo genome editing applications.
Key content categories feature earnings reports, FDA regulatory updates, scientific publication highlights, and strategic collaboration news. Bookmark this page for direct access to primary source materials from Sangamo Therapeutics, maintaining your awareness of critical developments in precision genomic medicine.
In the PR, Sangamo Therapeutics reported recent business highlights, including raising $24 million in gross proceeds, progress in neurology pipeline, completion of dosing in Phase 1/2 STAAR study for Fabry disease, and ongoing discussions with potential Fabry collaboration partners. Pfizer anticipates BLA and MAA submissions for Hemophilia A collaboration in early 2025. Financially, Sangamo reported a net loss of $49.1 million in Q1 2024 compared to a net income of $21.1 million in Q1 2023, with revenues decreasing to $0.5 million from $158.0 million in the same period in 2023. The non-GAAP total operating expenses decreased to $43.6 million in Q1 2024 from $69.5 million in Q1 2023. Cash and cash equivalents were $54.4 million as of March 31, 2024.
Sangamo Therapeutics, Inc. presented pre-clinical data on their innovative Modular Integrase (MINT) technology, aimed at large-scale genome editing. The MINT platform utilizes Bxb1 to integrate large DNA sequences into the genome with potential applications in treating patients with unique mutations. The technology is designed to simplify manufacturing, reduce translocation risk, and enable targeted integration without the need for additional genome editing tools. The company views the MINT platform as a valuable tool for neurology-focused indications and potential collaborations in human disease and agricultural biotech.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) has announced the release of its first quarter 2024 financial results on Thursday, May 9, 2024. The company will hold a conference call at 4:30 p.m. Eastern on the same day to discuss financial results and provide business updates.
FAQ
What is the current stock price of Sangamo Therapeutics (SGMO)?
What is the market cap of Sangamo Therapeutics (SGMO)?
